Search results (78)
« Back to NewsGlobal study highlights the extent and impact of drug-resistant enteric fever and the urgent need for new approaches
23 December 2019
MORU Bangkok Publication Research
A new study conducted by Christiane Dolecek and colleagues analysed data on antimicrobial resistance of the bacteria Salmonella Typhi and Salmonella Paratyphi, from around the globe, spanning the time from 1990 to 2018. The study highlights the impact of drug resistance and the urgent need for interventions.
New research supports co-administration of primaquine with artemisinin-based combination therapies for P. vivax malaria
8 October 2019
MORU Bangkok Publication Research
An individual patient data meta-analysis of 2,017 patients from 19 studies has found a high risk of recurrence following treatment of P. vivax malaria with artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) unless they are co-administered with primaquine. The research supports recommendations that these artemisinin-based combination therapies (ACT) should be combined with primaquine.
MORU's new Critical Care Asia Network: 42 ICUs in 9 countries
18 September 2019
In partnership with the Wellcome Innovations Flagship Programme, MORU launched its Critical Care Asia Network project with its first investigators’ meeting on 19-20 Aug in Bangkok. The project will establish an Asian ICU network across 42 ICUs in nine countries and implement a setting-adapted electronic registry.
Antimalarial treatments less effective in severely malnourished children
24 July 2019
MORU Bangkok Publication Research
MORU researchers have found that severe malnutrition is associated with lower exposure to the antimalarial drug lumefantrine in children treated with artemether-lumefantrine, the most common treatment for uncomplicated falciparum malaria. The study, which is the first to specifically address this, calls urgently for further research into optimised dosing regimens for undernourished children.
Rapidly spreading multidrug-resistant parasites render frontline malaria drug ineffective in southeast Asia
23 July 2019
MORU Bangkok Publication Research
A rapidly evolving multi-drug resistant lineage of P. falciparum malaria parasites continues to spread in South East Asia, leading to alarmingly high treatment failure rates in Cambodia, Thailand and Vietnam for DHA-piperaquine, one of the world’s most important anti-malaria drugs.
New study shows faster way to cure vivax malaria
19 July 2019
MORU Bangkok Publication Research
A large clinical trial in Africa and Asia has shown that a 7 day course of high dose primaquine, a drug used to treat P. vivax malaria, is well tolerated and just as effective as the current standard 14 day regimen, according to a study published this week in The Lancet. These findings have important implications for the treatment and elimination of vivax malaria in the Asia Pacific.
Research to investigate the prevalence and causes of rickets in remote NW Myanmar
17 July 2019
Medical Action Myanmar and MOCRU health teams identified a number of children with rickets in remote areas of Myanmar. MOCRU director Frank Smithuis presented the findings of clinical screening to the Minister of Health, alongside treatment results and a plan for a large survey to investigate the prevalence of vitamin D deficiency and its underlying causes.
Longer follow-up needed for malaria treatment in pregnant women
2 July 2019
New research by Makoto Saito and colleagues at SMRU found that a longer follow-up is required to assess antimalarial drug efficacy in pregnant women. This was found across all drugs assessed in low malaria transmission settings. The report’s authors have called for guidelines specifically for pregnant women and further investigation of optimal follow-up periods in high malaria transmission settings.
World Malaria Day seminar 2019 - Antimalarial treatments for vulnerable groups
30 April 2019
To mark World Malaria Day on 25 April WWARN’s Dr Makoto Saito and Professor Joel Tarning from the Mahidol Oxford Tropical Medicine Research Unit and Head of WWARN Pharmacometrics presented their work on prevention and treatment of malaria in vulnerable groups at a seminar hosted by the Centre for Tropical Medicine and Global Health
Cherry's story: a career launched by first-hand experience and a good mentor
3 April 2019
How do you go about building all the skills you need at the start of your research career? Cherry Lim from our MORU unit in Bangkok, Thailand, was lucky to find a good mentor who guided her through this journey, but her own ceaseless curiosity and excitement about research were also important.
Tracking resistance results presented at Westminster, UK Houses of Parliament
26 March 2019
Rob van der Pluijm presented encouraging findings from TRAC II trial analyses of Triple Artemisinin Combination Therapies to the All-Party Parliamentary Group on Malaria & NTDs on March 19th in Westminster at the Houses of Parliament.
Mass drug administration against malaria seen effective
6 March 2019
Lorenz Von Seidlein tells SciDev.Net that mass drug administration as “presumptive treatment” to clear the parasite reservoir was carried out in eight villages spread across Cambodia, Lao PDR, Myanmar and Vietnam. By the third month, the prevalence of P. falciparum had decreased by 92 % in those villages. Over the subsequent nine months, P. falciparum infections returned but stayed well below baseline levels, showing that MDA can stop transmission of falciparum malaria and reduce its prevalence in SE Asia, where resistance to artemisinin has hampered elimination efforts.
Katherine Plewes earns Canadian grant for KIMORU based study
1 March 2019
Working closely with the University of British Columbia (UBC)'s Support Program to Advance Research Capacity (SPARC), MORU Malaria Researcher Dr Katherine Plewes was recently awarded a 3-year, C$971,551 grant for her study on Evaluating the renoprotective effect of acetaminophen in pediatric severe falciparum malaria: A randomized controlled trial.
DeTACT study begins; will develop two new, safe malaria treatments
12 February 2019
On 24-25 Jan 2019, investigators met in Bangkok to launch the Developing Triple Artemisinin-based Combination Therapies (DeTACT) Project. Led by MORU and funded by UKaid and the UK Department for International Development (DfID), DeTACT is a large, 14 site trial in 8 African and 5 Asian countries that will study the efficacy, safety and tolerability of two Triple Artemisinin Combination Therapy (TACT) combinations, using combinations of existing antimalarial drugs.
Latest WWARN publication identifies 15 new mutant alleles in the Kelch-13 gene
18 January 2019
A recent WWARN individual patient meta-analysis has gathered 18 published and unpublished studies from Africa and Asia to explore the relationships between identified Kelch 13 mutant alleles and delayed parasite clearance. The study results show one P. falciparum specific mutant and 20 pfk13 propeller region mutant alleles are strongly associated with the slow clearance phenotype, including 15 mutations that have not been confirmed before. It was reassuring that no pfk13 alleles associated with slow parasite clearance were observed in the parasites from African studies gathered between 2000-2017.
Fighting malaria in the remote reaches of Cambodia
16 January 2019
Malaria causes nearly half a million deaths worldwide every year. Ninety percent of them are in sub-Saharan Africa, where poor infrastructure limits delivery of drugs. But now there is worry that those drugs are losing effectiveness as disease strains become resistant. PBS News Hour special correspondent Fred de Sam Lazaro reports from Cambodia, where scientists are researching and tracking new outbreaks.
Malaria in Cambodia on Sky News
16 January 2019
Doctors in Northern Cambodia are trialling a new drug combination therapy in a bid to stop the spread of drug resistant strains of malaria.
New Study Group to determine the effects of pregnancy on piperaquine pharmacokinetics
18 December 2018
A new Piperaquine Pharmacokinetics in Pregnancy Study Group is now open for participation at WWARN. The analysis hopes to determine the effect of pregnancy on the pharmacokinetic (PK) properties of piperaquine and contribute evidence to inform decisions on the use and optimal dosing of piperaquine in pregnant women.
The large footprint of the Centre for Tropical Medicine and Global Health
12 December 2018
This article, written by Professor Nick Day at MORU and published in the November 2018 issue of the Oxford Alumni Newsletter, describes in a nutshell all the good work our Centre is doing to promote Global Oxford.
The fight against malaria has reached a standstill
20 November 2018
Progress against malaria has stalled, and the disease remains a significant threat to billions of people despite the expensive, decades-long efforts to contain it. In an encouraging development, MORU reported complete success in curing hundreds of patients in Southeast Asia with new three-drug combinations mixing fast-acting artemisinin with two longer-lasting drugs. It it hoped that triple therapy should become the standard for malaria treatment.
Reviewing the Cardiovascular Safety Profile of Antimalarial Drugs
9 November 2018
MORU Bangkok Publication Research
A systematic review analyses the results of 177 trials conducted between 1982 and 2016, including 18,436 patients who underwent electrocardiographic evaluation during malaria clinical trials. Nick White and colleagues found that serious cardiovascular side effects, which include sudden cardiac death, are very rare in the treatment of malaria with quinoline antimalarials. The work emphasises the importance of continued pharmacovigilance with the increasing use of quinoline antimalarials in mass treatment strategies such as intermittent preventative treatment and mass drug administration.
Positive results in fight against malaria in remote parts of Myanmar
7 November 2018
The incidence of malaria has continued to drop dramatically in remote rural villages in Myanmar after community workers trained only to detect and treat malaria began providing basic health care as well as malaria services, researchers affiliated with MOCRU, our Myanmar-Oxford Clinical Research Unit, have said.
Provide basic health services in remote villages to eliminate malaria
24 October 2018
The incidence of malaria cases continued to drop dramatically in rural and remote Myanmar villages after community workers trained only to detect and treat malaria began providing basic health care as well as malaria services. Adding the health services to malaria control benefitted the villagers access to health and improved malaria services – paving the way for malaria elimination.
Overcoming the challenges of rural surveys in developing countries
28 September 2018
In this Science blog, field researchers, Dr Giacomo Zanello, Dr Marco Haenssgen, Ms Nutcha Charoenboon and Mr Jeffrey Lienert explain the importance of continuing to improve survey research techniques when working in rural areas of developing countries.
Tackling drug resistance on Asian farms with maps and a dictionary
12 September 2018
MORU is participating in a project to reduce antibiotic resistance on farms in Asia by educating farmers. In his first 12 years working as a vet in Bangladesh, Bikash Chandra Saha routinely prescribed antibiotics. Then he learned of the devastating impact of antimicrobial resistance on human health - and it revolutionized his treatment choices.
Myanmar researchers awarded research grants
12 September 2018
Dr Myo Maung Maung Swe and Htet Htet Aung from our MOCRU unit in Myanmar were awarded grants by the International Society for Infectious Diseases and Wellcome. Myo Maung will study antibiotics use and antimicrobial resistance public awareness in Myanmar; Htet Htet will conduct a study on Ethical challenges when offering pregnant women with Hepatitis B short course treatment to prevent transmission.
Study details high hidden economic costs of antibiotic consumption
4 September 2018
MORU Bangkok Publication Research
A team of researchers led by Yoel Lubell at MORU and IDDO used data from the USA and Thailand to link the consumption of antibiotics with the direct and indirect costs of treating patients for five drug-resistant bacterial infections.
Malaria’s ticking time bomb
26 July 2018
Scientists are racing to stamp out the disease in Southeast Asia before unstoppable strains spread. This article features MORU, SMRU and colleagues, and explains what is happening and what we are doing to eliminate drug-resistant malaria in Southeast Asia before it spreads
Small children and pregnant women may be underdosed with widely used antimalarial drug
13 June 2018
MORU Bangkok Publication Research
Current recommended treatment regimens for the most widely used medicine for uncomplicated Plasmodium falciparum malaria may be sub-optimal for small children and pregnant women according to a study led by Professor Joel Tarning.
Safety doubts unwarranted, important anti-malarial drug DHA-PPQ is safe to use
8 June 2018
MORU Bangkok Publication Research
One of the world’s most widely used anti-malarial drugs is safe to use, say researchers, after a thorough review and analysis of nearly 200,000 malaria patients who’d taken the drug dihydroartemisinin-piperaquine (DHA-PPQ). There is such a low risk of sudden unexpected death from DHA-PPQ, one of the world’s most effective medicines to treat malaria, that there is no need to limit its current use.
New age-based regimen for single low-dose primaquine to block malaria transmission
25 May 2018
MORU Bangkok Publication Research
Primaquine can be used to prevent the transmission of falciparum malaria from human to mosquito. Bob Taylor and colleagues at the Mahidol Oxford Research Unit (MORU) have developed an age-based regimen for single low-dose primaquine to block the transmission of malaria in sub-Saharan Africa.
Using management thinking to fight the superbug crisis
11 May 2018
Dr Marco J Haenssgen discusses the application of management thinking to solving the growing global problem of antimicrobial resistance.
Getting rid of malaria possible, if we try something new, say experts
25 April 2018
MORU Bangkok Publication Research
The rapid elimination of potentially untreatable P. falciparum malaria in South-East Asia is possible, according to a ground-breaking new study published today in The Lancet. The study authors say that setting up community-based malaria clinics for early diagnosis, treatment and monitoring, combined with mass antimalarial drug administration (MDA) to everyone living in ‘hotspot’ areas.
The frontline fight against deadly malaria parasites threatening a new global emergency
20 April 2018
ITV News has travelled across the world to report on the growing global threat of the spread of deadly drug-resistant 'super bugs'. In the first of their three-part series, they investigate the frontline fight against deadly malaria parasites in South East Asia threatening a new global emergency.
UK to fund MORU study to develop two new, safe malaria treatments
20 April 2018
18 April 2018 (London) – The United Kingdom’s Department for International Development (DFID) announced that it will commit £9.2 million (USD 13.15 million) of research funding to DeTACT (Development of Triple Artemisinin Combination Therapies), a large multi-centre trial in 5 Asian and 10 African countries that aims to develop two new safe and effective malaria treatments using combinations of existing antimalarial drugs.
UK government announces further support in the fight against malaria
17 April 2018
As the second largest international donor, the UK has been at the forefront of efforts to reduce the number of cases for many years by investing in treatment, prevention and research, including the fight against the threat of drug resistance. The UK has announced further support for the fight against malaria to save more than 120,000 lives ahead of a Malaria Summit tomorrow with Commonwealth leaders.
The town that breeds resistance to Malaria drugs
10 April 2018
Pailin, a small settlement nestling in tropical rainforest near Cambodia’s border with Thailand, lies at the heart of a region that has seen successive waves of resistance to malaria drugs arise in local people and then spread across the globe. As new waves of the disease threaten our health, worried scientists want to conduct a mass inoculation in a Cambodian region where new vaccines always seem to stop being effective.
Paracetamol protects kidney in severe malaria patients
10 April 2018
MORU Bangkok Publication Research
Giving paracetamol (acetaminophen) to patients ill with severe malaria made them less likely to develop potentially fatal kidney failure. Each year severe malaria causes close to half a million deaths globally. Acute kidney injury occurs in 40% of adults and at least 10% of children with severe malaria, killing an estimated 40% of these adults and 12-24% of the children. The study reported for the first time that giving regular doses of paracetamol protects the kidney in adult patients with severe falciparum malaria.
FIEBRE study kicks off; aims to reveal leading causes of fever and tackle AMR
16 March 2018
FIEBRE aims to design new evidence-based guidelines to manage fever, thereby ensuring that patients get drugs that give them the best chance of recovery, and thereby help stop the spread of antimicrobial resistance (AMR), a major global health problem.
This disease kills half the people it infects. So why isn’t more being done?
23 February 2018
Melioidosis is a bacterial infection that quietly causes thousands of deaths each year. Meet Direk Limmathurotsakul, the doctor who made it his mission to make the world take notice.